Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperparathyroidism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Hyperparathyroidism. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-006645-41 Sponsor Protocol Number: SLAZ-Heuvel Start Date*: 2008-06-13
    Sponsor Name:Sint Lucas Andreas Hospital
    Full Title: The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Medical condition: Secondary hyperparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004136-30 Sponsor Protocol Number: 20130213 Start Date*: 2014-03-05
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    18.0 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) BE (Completed) AT (Completed) ES (Completed) PT (Completed) LT (Completed) PL (Completed) CZ (Completed) DK (Completed) LV (Completed) DE (Completed) GR (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002808-41 Sponsor Protocol Number: 20120231(KAI-4169-008) Start Date*: 2013-01-22
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemod...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    16.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) SE (Completed) ES (Completed) IT (Completed) AT (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021041-42 Sponsor Protocol Number: 25051954 Start Date*: 2011-01-28
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study
    Medical condition: Renal transplant patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005405-20 Sponsor Protocol Number: B08103 Start Date*: 2008-12-05
    Sponsor Name:Department of Medicine, Helsinki University Central Hospital
    Full Title: Bisfosfonaattien vaikutus luuntiheyteen ja luun uusiutumiseen leikkauksen jälkeen primaarissa hyperparatyreoosissa.
    Medical condition: Potilailla on primaari hyperparatyreoosi ja osteoporoosi. Hyperparatyreoosin hoidoksi on suunniteltu leikkaushoitoa.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020707 Hyperparathyroidism primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007017-76 Sponsor Protocol Number: 01PTHi Start Date*: 2009-03-24
    Sponsor Name:Josep M Cruzado
    Full Title: Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal.
    Medical condition: Hiperparatiroidismo secundario post trasplante renal
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005051-28 Sponsor Protocol Number: 20140336 Start Date*: 2016-08-22
    Sponsor Name:Amgen Inc
    Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Sec...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-009502-79 Sponsor Protocol Number: ipermen Start Date*: 2009-06-18
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyr...
    Medical condition: Primary hyperparathyroidism in patients with MEN1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020707 Hyperparathyroidism primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018861-53 Sponsor Protocol Number: W10-002 Start Date*: 2010-04-23
    Sponsor Name:Leiden University Medical Center
    Full Title: Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation
    Medical condition: Patients with primary hyperparathyroidism due to a germline mutation in the MEN-1 gene
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001704-23 Sponsor Protocol Number: PHPT_002/08 Start Date*: 2009-09-03
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Chirurgie
    Full Title: Primary hyperparathyroidism: does a systematic treatment improve the calcium and bone metabolism after successful surgery? – Part II Systematic treatment of patients with neither osteopenia nor os...
    Medical condition: Hypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents hungry bone- syndrome a...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020707 Hyperparathyroidism primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002806-31 Sponsor Protocol Number: 20120230(KAI-4169-007) Start Date*: 2013-02-12
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    14.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) SE (Completed) HU (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004958-18 Sponsor Protocol Number: 20130356 Start Date*: 2014-07-14
    Sponsor Name:Amgen, Inc.
    Full Title: A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Medical condition: Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) IT (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed) PT (Completed) DE (Completed) Outside EU/EEA GR (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-011378-14 Sponsor Protocol Number: M10-967 Start Date*: 2009-11-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary H...
    Medical condition: Secondary hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020708 Hyperparathyroidism secondary LLT
    12.0 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) ES (Completed) PT (Completed) GB (Completed) SE (Completed) IT (Completed) GR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006380-36 Sponsor Protocol Number: APPLE Start Date*: 2008-11-27
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH...
    Medical condition: Persistent secondary hyperparathyroidism in renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012943-41 Sponsor Protocol Number: 20070277 Start Date*: 2010-02-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Underg...
    Medical condition: Reduction of hypercalcemia in subjects with primary hyperparathyroidism (HPT) who meet criteria for parathyroidectomy on the basis of corrected total serum calcium, but who are unable to undergo pa...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002805-23 Sponsor Protocol Number: 20120229(KAI-4169-006) Start Date*: 2013-01-22
    Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    16.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001043-22 Sponsor Protocol Number: HECT01206 Start Date*: 2007-11-21
    Sponsor Name:Genzyme Europe BV
    Full Title: A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients
    Medical condition: Secondary hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002075-40 Sponsor Protocol Number: 20050182 Start Date*: 2006-10-04
    Sponsor Name:Amgen Inc.
    Full Title: EVOLVE - Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) AT (Completed) DE (Completed) IE (Completed) BE (Completed) PT (Completed) DK (Completed) GB (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017999-25 Sponsor Protocol Number: 20090005 Start Date*: 2010-11-12
    Sponsor Name:Amgen Inc
    Full Title: An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to < 6 Years with Chronic Kidney Di...
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004618-40 Sponsor Protocol Number: 20110100 Start Date*: Information not available in EudraCT
    Sponsor Name:Amgen Inc.
    Full Title: An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease an...
    Medical condition: Secondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Temporarily Halted) PL (Completed) HU (Completed) CZ (Completed) IT (Completed) SK (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:23:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA